As we progress through 2026, the clinical narrative for Mounjaro in Dubai has expanded far beyond the scope of weight loss. While shedding excess pounds remains a primary goal for many, the true medical value of this dual-agonist therapy lies in its ability to resolve life-threatening comorbidities. Recent landmark studies, including the SURMOUNT-OSA trials published in early 2026, have...